Answers are grounded in this paper and cite their sources.
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with poor prognosis. A transcriptomic-based algorithm called Purity Independent Subtyping of Tumors (PurIST) relies on transcriptomic expression of a defined set of genes to stratify PDAC into classical and basal-like molecular subtypes and assigns a confidence level to the subtypes as either “strong,” “likely,” or “lean.” In this retrospective study, we apply PurIST to Appalachian and non-Appalachian patient cohorts and assess differences between the two groups. Methods: This 13-site study includes 780 PDAC patients. Patients were divided into Appalachian and non-Appalachian cohorts according to Appalachian Regional Commission guidelines, and differences in PurIST classification, tobacco use, and alcohol use were analyzed. Results: Individuals from Appalachian regions were more likely to receive a subtype classification from PurIST with “strong” confidence as opposed to “likely” or “lean” (p = 0.018). Although all sequencing passed quality control, there were significantly more individuals with borderline sequencing metrics in Appalachia (p = 0.0015) and removing those individuals resulted in non-significant differences in PurIST confidence levels between the two populations (p = 0.11). We did not observe any significant difference between basal and classical subtype classification in Appalachia (p = 0.15). The age at clinical record creation in Appalachia was significantly younger than non-Appalachian regions (p = 0.00052), and an exploratory analysis showed that individuals aged ≥84 were significantly more likely to have basal-like tumor classifications (p = 0.0012). Appalachian patients were more likely to have a history of smoking (p = 0.018) and less likely to report alcohol consumption (p = 0.00023). Conclusions: We conducted the largest comparison of the PurIST algorithm in Appalachia to date and found that PurIST is more likely to have higher confidence in molecular subtype classifications for Appalachian PDAC tumors compared to non-Appalachian tumors, which may partly be due to the quality control thresholds for sequencing. If PurIST is to be considered as a prognostic or decision-making tool for PDAC patients, we must account for variability in sequencing and expression patterns between different populations and institutions.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: